SYH2053
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 04, 2025
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
(clinicaltrials.gov)
- P1 | N=39 | Completed | Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not yet recruiting ➔ Completed | Trial primary completion date: Aug 2024 ➔ Dec 2024
Trial completion • Trial primary completion date • Dyslipidemia • APOB
January 29, 2024
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
(clinicaltrials.gov)
- P1 | N=39 | Not yet recruiting | Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
New P1 trial • Dyslipidemia
1 to 2
Of
2
Go to page
1